公开(公告)号：US12208071B2

公开(公告)日：2025-01-28

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  A61K31/155 ,  A61K31/366 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/64 ,  A61K31/702 ,  A61K31/7032 ,  A61K38/28 ,  A61K38/31 ,  A61K45/06 ,  C07C67/00 ,  C07C67/343 ,  C07C201/12 ,  C07C209/36 ,  C07C231/02 ,  C07C231/12 ,  C07C309/24 ,  C07C315/04 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

公开(公告)号：US20210121422A1

公开(公告)日：2021-04-29

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED ,  METAVANT SCIENCES GMBH

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  C07C309/24 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  A61K38/28 ,  A61K38/31 ,  A61K31/7032 ,  A61K31/702 ,  A61K31/64 ,  A61K31/366 ,  A61K31/455 ,  A61K45/06 ,  C07C315/04 ,  C07C201/12 ,  C07C209/36 ,  C07C67/343 ,  C07C67/00 ,  C07C231/02 ,  C07C231/12 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.